A Biotech Bash - Recs and Wrecks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bash - Recs and Wrecks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (79)	8/29/1997 9:06:00 AM
From: r. peter Dale	of 171

Miljenko - Just a brief clarification of your CNS related post and a question: My general understanding of your outline of the Sibia drug(s): compounds are NAchR agonists. Nigral (i.e DA) neurons have many NAChR. Drug stimulates DA neurons to release NT but at level not in line with AchR activation. Clinical trials indicate some efficacy in relieving PD motor symptoms related to nigral loss but probable toxicity issue with poor clearance of drug. Question: What happens to similar PD patients with muscarinic agonists? To messy in the CNS? Sibia doing anything in the MAchR field addressing nucleus basalis loss in Alzheimer's? TIA Best wishes, Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next